Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| METLIFE INCMET · Entity 488 | Director | October 01, 2026 | October 05, 2026 |
| VERTEX PHARMACEUTICALS INC / MAVRTX · Entity 2875 | Director | May 01, 2026 | May 05, 2026 |
| agilon health, inc.AGL · Entity 4698 | Director | June 02, 2026 | June 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
METLIFE INC
Report date October 01, 2026 · Filed October 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 25,929 |
Reported balance
After 2026-10-01 transaction · row 1
1 source rowRow 1 · 2026-10-01 · Grant · Acquired 544 · Balance 25,929 F1: MetLife, Inc.'s non-management director compensation arrangements pay a portion of non-management director retainer fees in MetLife, Inc. common stock. The director elected to defer receipt of these shares under the MetLife Deferred Compensation Plan for Non-Management Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: MetLife, Inc.'s non-management director compensation arrangements pay a portion of non-management director retainer fees in MetLife, Inc. common stock. The director elected to defer receipt of these shares under the MetLife Deferred Compensation Plan for Non-Management Directors.
VERTEX PHARMACEUTICALS INC / MA
Report date May 01, 2026 · Filed May 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,378 |
Ending reported balance
After 2026-05-01 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-05-01 · Grant · Acquired 943 · Balance 3,174 F1: Restricted stock unit award that vests, subject to certain limited exceptions, on the first anniversary of the grant date. Row 2 · 2026-05-01 · Disposition to issuer · Disposed 796 · Balance 2,378 F2: Upon the vesting of restricted stock units granted to Ms. McKenzie on May 1, 2025, Ms. McKenzie deferred the receipt of 796 shares of common stock and received instead 796 deferred stock units pursuant to our deferred compensation plan. As a result, Ms. McKenzie is reporting the disposition of 796 shares of common stock in exchange for an equal number of deferred stock units. |
| Deferred Stock UnitsSEC Table II · derivative / convertible security | Direct | 7,787.483 |
Reported balance
After 2026-05-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-05-01 · Grant · Acquired 796 · Balance 7,787.483 F3: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death. F2: Upon the vesting of restricted stock units granted to Ms. McKenzie on May 1, 2025, Ms. McKenzie deferred the receipt of 796 shares of common stock and received instead 796 deferred stock units pursuant to our deferred compensation plan. As a result, Ms. McKenzie is reporting the disposition of 796 shares of common stock in exchange for an equal number of deferred stock units. |
| Common StockSEC Table I · non-derivative | IndirectHeld in Trust | 207 |
Reported balance
Holding disclosure · report date 2026-05-01 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 207 |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock unit award that vests, subject to certain limited exceptions, on the first anniversary of the grant date.
F2: Upon the vesting of restricted stock units granted to Ms. McKenzie on May 1, 2025, Ms. McKenzie deferred the receipt of 796 shares of common stock and received instead 796 deferred stock units pursuant to our deferred compensation plan. As a result, Ms. McKenzie is reporting the disposition of 796 shares of common stock in exchange for an equal number of deferred stock units.
F3: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death.
agilon health, inc.
Report date June 02, 2026 · Filed June 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,633 |
Reported balance
After 2026-06-02 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-02 · Grant · Acquired 2,133 · Balance 7,633 F1: Restricted stock units that vest in full on June 2, 2027, subject to continued service as a director. F2: The amount of securities beneficially owned following the reported transaction reflects the 1 for 25 reverse stock split of the Issuer's issued and outstanding common stock effective March 30, 2026. F3: Includes restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units that vest in full on June 2, 2027, subject to continued service as a director.
F2: The amount of securities beneficially owned following the reported transaction reflects the 1 for 25 reverse stock split of the Issuer's issued and outstanding common stock effective March 30, 2026.
F3: Includes restricted stock units.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Change Healthcare Inc.
Report date October 03, 2022 · Filed October 05, 2022
Section 16 reporting ended · disclosed 2022-10-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 1
1 source rowRow 1 · 2022-10-03 · Disposition to issuer · Disposed 40,706 · Balance 0 F1: On October 3, 2022, UnitedHealth Group Incorporated ("UnitedHealth Group") acquired Change Healthcare Inc. (the "Issuer") pursuant to that certain Agreement and Plan of Merger dated as of January 5, 2021 (the "Merger Agreement") by and among the Issuer, UnitedHealth Group and Cambridge Merger Sub Inc., a wholly owned subsidiary of UnitedHealth Group ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly owned subsidiary of UnitedHealth Group. At the effective time of the Merger (the "Effective Time"), each issued and outstanding share of common stock, par value $0.001 per share, of the Issuer (the "Common Stock") (other than certain excluded shares) automatically converted into the right to receive $25.75 per share in cash, without interest and less any applicable holding tax. F2: At the Effective Time of the Merger, all deferred stock units of the Issuer automatically vested and were automatically converted into UnitedHealth Group deferred stock units calculated by taking the merger consideration of $25.75 per share of Common Stock and dividing it by the volume weighted average of the closing sale prices per share of UnitedHealth Group common stock on each of the five full consecutive trading days ending on and including the third business day prior to the Merger closing date and continue to be subject to the same terms and conditions (including settlement terms) as were applicable to the Issuer deferred stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: On October 3, 2022, UnitedHealth Group Incorporated ("UnitedHealth Group") acquired Change Healthcare Inc. (the "Issuer") pursuant to that certain Agreement and Plan of Merger dated as of January 5, 2021 (the "Merger Agreement") by and among the Issuer, UnitedHealth Group and Cambridge Merger Sub Inc., a wholly owned subsidiary of UnitedHealth Group ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly owned subsidiary of UnitedHealth Group. At the effective time of the Merger (the "Effective Time"), each issued and outstanding share of common stock, par value $0.001 per share, of the Issuer (the "Common Stock") (other than certain excluded shares) automatically converted into the right to receive $25.75 per share in cash, without interest and less any applicable holding tax.
F2: At the Effective Time of the Merger, all deferred stock units of the Issuer automatically vested and were automatically converted into UnitedHealth Group deferred stock units calculated by taking the merger consideration of $25.75 per share of Common Stock and dividing it by the volume weighted average of the closing sale prices per share of UnitedHealth Group common stock on each of the five full consecutive trading days ending on and including the third business day prior to the Merger closing date and continue to be subject to the same terms and conditions (including settlement terms) as were applicable to the Issuer deferred stock units.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 03, 2023 Filed Apr 5, 2023 21:04 UTC | METLIFE INC MET · Entity 488 | GrantCommon Stock | 755 | $57.97 | $43,767.35 |
DisclosureSEC source: 0001099219-23-000137 · wf-form4_168072865289910.xml · nonDerivative · entry 1 MCKENZIE DIANA · CIK 0001754648 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,257 F1 · kind: MetLife, Inc.'s non-management director compensation arrangements pay a portion of non-management director retainer fees in MetLife, Inc. common stock. The director elected to defer receipt of these shares under the MetLife Deferred Compensation Plan for Non-Management Directors. Read SEC document |
| March 14, 2023 Filed Mar 16, 2023 20:36 UTC | METLIFE INC MET · Entity 488 | GrantCommon Stock | 121 | $59.07 | $7,147.47 |
DisclosureSEC source: 0001099219-23-000108 · wf-form4_167899895118897.xml · nonDerivative · entry 1 MCKENZIE DIANA · CIK 0001754648 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,502 F1 · kind: Imputed reinvestment of dividends on deferred shares pursuant to the MetLife Deferred Compensation Plan for Non-Management Directors. Deferred shares represent shares of MetLife, Inc. common stock that have become payable, but receipt of which the director has deferred. Read SEC document |
| February 28, 2023 Filed Mar 3, 2023 00:03 UTC | METLIFE INC MET · Entity 488 | GrantCommon Stock | 31 | $71.73 | $2,223.63 |
DisclosureSEC source: 0001099219-23-000089 · wf-form4_167780180660073.xml · nonDerivative · entry 1 MCKENZIE DIANA · CIK 0001754648 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,381 F1 · kind: MetLife, Inc.'s non-management director compensation arrangements pay a portion of non-management director retainer fees in MetLife, Inc. common stock. The director elected to defer receipt of these shares under the MetLife Deferred Compensation Plan for Non-Management Directors. Read SEC document |
| February 17, 2023 Filed Feb 22, 2023 22:20 UTC | agilon health, inc. AGL · Entity 4698 | GrantOptions (Rights to Buy) · Derivative | 11,104 | $0.00 Strike: $22.79 | $0.00 |
DisclosureSEC source: 0001209191-23-011763 · doc4.xml · derivative · entry 2 MCKENZIE DIANA · CIK 0001754648 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,104 Underlying: Common Stock · 11,104 shares Expires 2033-02-17 F2 · derivative.exercise_date: Options that vest in three equal installments on each anniversary of February 17, 2023, subject to continued service as a director. F2 · derivative.expiration_date: Options that vest in three equal installments on each anniversary of February 17, 2023, subject to continued service as a director. Read SEC document |
| February 17, 2023 Filed Feb 22, 2023 22:20 UTC | agilon health, inc. AGL · Entity 4698 | GrantCommon Stock | 1,078 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-011763 · doc4.xml · nonDerivative · entry 1 MCKENZIE DIANA · CIK 0001754648 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,078 F1 · shares: Restricted stock units that vest in full on February 17, 2024, subject to continued service as a director. Read SEC document |
| January 13, 2023 Filed Jan 18, 2023 21:07 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantDeferred Stock Units · Derivative | 100.53 | $298.42 | $30,000.16 |
DisclosureSEC source: 0001209191-23-003703 · doc4.xml · derivative · entry 1 MCKENZIE DIANA · CIK 0001754648 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,027.368 Underlying: Common Stock · 100.53 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death. F1 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death. F1 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 21:27 UTC | METLIFE INC MET · Entity 488 | GrantCommon Stock | 520 | $72.15 | $37,518.00 |
DisclosureSEC source: 0001099219-23-000027 · wf-form4_167295405353494.xml · nonDerivative · entry 1 MCKENZIE DIANA · CIK 0001754648 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,350 F1 · kind: MetLife, Inc.'s non-management director compensation arrangements pay 50% of non-management director retainer in MetLife, Inc. common stock. The director elected to defer receipt of these shares under the MetLife Deferred Compensation Plan for Non-Management Directors. Read SEC document |
| December 14, 2022 Filed Dec 16, 2022 21:25 UTC | METLIFE INC MET · Entity 488 | GrantCommon Stock | 94 | $72.84 | $6,846.96 |
DisclosureSEC source: 0001099219-22-000203 · wf-form4_167122589949781.xml · nonDerivative · entry 1 MCKENZIE DIANA · CIK 0001754648 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,830 F1 · kind: Imputed reinvestment of dividends on deferred shares pursuant to the MetLife Deferred Compensation Plan for Non-Management Directors. Deferred shares represent shares of MetLife Inc. common stock that have become payable, but receipt of which the director has deferred. Read SEC document |
| October 14, 2022 Filed Oct 18, 2022 20:25 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantDeferred Stock Units · Derivative | 101.072 | $296.82 | $30,000.19 |
DisclosureSEC source: 0000899243-22-033743 · doc4.xml · derivative · entry 1 MCKENZIE DIANA · CIK 0001754648 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,926.838 Underlying: Common Stock · 101.072 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death. F1 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death. F1 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 20:28 UTC | METLIFE INC MET · Entity 488 | GrantCommon Stock | 599 | $62.62 | $37,509.38 |
DisclosureSEC source: 0001099219-22-000166 · wf-form4_166500172332928.xml · nonDerivative · entry 1 MCKENZIE DIANA · CIK 0001754648 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,735 F1 · kind: MetLife, Inc.'s non-management director compensation arrangements pay 50% of non-management director retainer fees in MetLife, Inc. common stock. The director deferred receipt under the MetLife Deferred Compensation Plan for Non-Management Directors. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 20:31 UTC | Change Healthcare Inc. CHNG · Entity 15437 | Disposition to issuerCommon Stock | 40,706 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-033009 · doc4.xml · nonDerivative · entry 1 MCKENZIE DIANA · CIK 0001754648 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: On October 3, 2022, UnitedHealth Group Incorporated ("UnitedHealth Group") acquired Change Healthcare Inc. (the "Issuer") pursuant to that certain Agreement and Plan of Merger dated as of January 5, 2021 (the "Merger Agreement") by and among the Issuer, UnitedHealth Group and Cambridge Merger Sub Inc., a wholly owned subsidiary of UnitedHealth Group ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly owned subsidiary of UnitedHealth Group. At the effective time of the Merger (the "Effective Time"), each issued and outstanding share of common stock, par value $0.001 per share, of the Issuer (the "Common Stock") (other than certain excluded shares) automatically converted into the right to receive $25.75 per share in cash, without interest and less any applicable holding tax. F2 · shares: At the Effective Time of the Merger, all deferred stock units of the Issuer automatically vested and were automatically converted into UnitedHealth Group deferred stock units calculated by taking the merger consideration of $25.75 per share of Common Stock and dividing it by the volume weighted average of the closing sale prices per share of UnitedHealth Group common stock on each of the five full consecutive trading days ending on and including the third business day prior to the Merger closing date and continue to be subject to the same terms and conditions (including settlement terms) as were applicable to the Issuer deferred stock units. F1 · price: On October 3, 2022, UnitedHealth Group Incorporated ("UnitedHealth Group") acquired Change Healthcare Inc. (the "Issuer") pursuant to that certain Agreement and Plan of Merger dated as of January 5, 2021 (the "Merger Agreement") by and among the Issuer, UnitedHealth Group and Cambridge Merger Sub Inc., a wholly owned subsidiary of UnitedHealth Group ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly owned subsidiary of UnitedHealth Group. At the effective time of the Merger (the "Effective Time"), each issued and outstanding share of common stock, par value $0.001 per share, of the Issuer (the "Common Stock") (other than certain excluded shares) automatically converted into the right to receive $25.75 per share in cash, without interest and less any applicable holding tax. F2 · price: At the Effective Time of the Merger, all deferred stock units of the Issuer automatically vested and were automatically converted into UnitedHealth Group deferred stock units calculated by taking the merger consideration of $25.75 per share of Common Stock and dividing it by the volume weighted average of the closing sale prices per share of UnitedHealth Group common stock on each of the five full consecutive trading days ending on and including the third business day prior to the Merger closing date and continue to be subject to the same terms and conditions (including settlement terms) as were applicable to the Issuer deferred stock units. Read SEC document |
| September 14, 2022 Filed Sep 16, 2022 20:26 UTC | METLIFE INC MET · Entity 488 | GrantCommon Stock | 98 | $66.41 | $6,508.18 |
DisclosureSEC source: 0001099219-22-000144 · wf-form4_166335995531873.xml · nonDerivative · entry 1 MCKENZIE DIANA · CIK 0001754648 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,136 F1 · kind: Imputed reinvestment of dividends on deferred shares pursuant to the MetLife Deferred Compensation Plan for Non-Management Directors. Deferred shares represent shares of MetLife, Inc. common stock that have become payable, but receipt of which the director has deferred. Read SEC document |
| July 15, 2022 Filed Jul 19, 2022 20:33 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantDeferred Stock Units · Derivative | 95.081 | $289.23 | $27,500.28 |
DisclosureSEC source: 0000899243-22-026342 · doc4.xml · derivative · entry 1 MCKENZIE DIANA · CIK 0001754648 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,825.766 Underlying: Common Stock · 95.081 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death. F1 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death. F1 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death. Read SEC document |
| June 21, 2022 Filed Jun 23, 2022 20:14 UTC | METLIFE INC MET · Entity 488 | GrantCommon Stock | 600 | $62.53 | $37,518.00 |
DisclosureSEC source: 0000937834-22-000081 · wf-form4_165601528143631.xml · nonDerivative · entry 1 MCKENZIE DIANA · CIK 0001754648 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,038 F1 · kind: MetLife, Inc.'s non-management director compensation arrangements pay 50% of non-management director retainer fees in MetLife, Inc. common stock. The director deferred receipt under the MetLife Deferred Compensation Plan for Non-Management Directors. Read SEC document |
| June 14, 2022 Filed Jun 16, 2022 20:29 UTC | METLIFE INC MET · Entity 488 | GrantCommon Stock | 100 | $61.86 | $6,186.00 |
DisclosureSEC source: 0000937834-22-000054 · wf-form4_165541132413217.xml · nonDerivative · entry 1 MCKENZIE DIANA · CIK 0001754648 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,438 F1 · kind: Imputed reinvestment of dividends on deferred shares pursuant to the MetLife Deferred Compensation Plan for Non-Management Directors. Deferred shares represent shares of MetLife Inc. common stock that have become payable, but receipt of which the director has deferred. Read SEC document |
| May 01, 2022 Filed May 3, 2022 20:48 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantDeferred Stock Units · Derivative | 1,842 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-016338 · doc4.xml · derivative · entry 4 MCKENZIE DIANA · CIK 0001754648 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,730.685 Underlying: Common Stock · 1,842 shares Expires not disclosed F2 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on the Issuer's board of directors, (ii) a change of control of the Issuer and (iii) Ms. McKenzie's disability or death. F1 · price: Upon the vesting of restricted stock units granted to Ms. McKenzie on May 1, 2021, Ms. McKenzie deferred the receipt of 1,842 shares of common stock and received instead 1,842 deferred stock units pursuant to the Issuer's deferred compensation plan. As a result, Ms. McKenzie is reporting the disposition of 1,842 shares of common stock in exchange for an equal number of deferred stock units. F2 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on the Issuer's board of directors, (ii) a change of control of the Issuer and (iii) Ms. McKenzie's disability or death. F2 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on the Issuer's board of directors, (ii) a change of control of the Issuer and (iii) Ms. McKenzie's disability or death. Read SEC document |
| May 01, 2022 Filed May 3, 2022 20:48 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 1,449 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-016338 · doc4.xml · nonDerivative · entry 2 MCKENZIE DIANA · CIK 0001754648 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,884 F3 · shares: Restricted stock unit award that vests, subject to certain limited exceptions, on the first anniversary of the grant date. Read SEC document |
| May 01, 2022 Filed May 3, 2022 20:48 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Disposition to issuerCommon Stock | 1,842 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-016338 · doc4.xml · nonDerivative · entry 1 MCKENZIE DIANA · CIK 0001754648 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,435 F1 · price: Upon the vesting of restricted stock units granted to Ms. McKenzie on May 1, 2021, Ms. McKenzie deferred the receipt of 1,842 shares of common stock and received instead 1,842 deferred stock units pursuant to the Issuer's deferred compensation plan. As a result, Ms. McKenzie is reporting the disposition of 1,842 shares of common stock in exchange for an equal number of deferred stock units. Read SEC document |
| April 25, 2022 Filed Apr 27, 2022 21:07 UTC | Change Healthcare Inc. CHNG · Entity 15437 | GrantCommon Stock | 7,658 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-010883 · form4.xml · nonDerivative · entry 1 MCKENZIE DIANA · CIK 0001754648 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,706 F1 · shares: Represents the grant of deferred stock units that vest on April 25, 2023. The shares subject to the units will be issued to the Reporting Person after the Reporting Person's separation from service from the Issuer. Read SEC document |
| April 14, 2022 Filed Apr 18, 2022 20:05 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantDeferred Stock Units · Derivative | 95.021 | $289.41 | $27,500.03 |
DisclosureSEC source: 0000899243-22-014961 · doc4.xml · derivative · entry 1 MCKENZIE DIANA · CIK 0001754648 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 888.685 Underlying: Common Stock · 95.021 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death. F1 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death. F1 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 20:09 UTC | METLIFE INC MET · Entity 488 | GrantCommon Stock | 532 | $70.50 | $37,506.00 |
DisclosureSEC source: 0001099219-22-000094 · wf-form4_164918937600679.xml · nonDerivative · entry 1 MCKENZIE DIANA · CIK 0001754648 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,338 F1 · kind: MetLife, Inc.'s non-management director compensation arrangements pay 50% of non-management director retainer fees in MetLife, Inc. common stock. The director deferred receipt under the MetLife Deferred Compensation Plan for Non-Management Directors. Read SEC document |
| March 14, 2022 Filed Mar 16, 2022 20:37 UTC | METLIFE INC MET · Entity 488 | GrantCommon Stock | 87 | $64.69 | $5,628.03 |
DisclosureSEC source: 0001099219-22-000074 · wf-form4_164746302367165.xml · nonDerivative · entry 1 MCKENZIE DIANA · CIK 0001754648 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,806 F1 · kind: Imputed reinvestment of dividends on deferred shares pursuant to the MetLife Deferred Compensation Plan for Non-Management Directors. Deferred shares represent shares of MetLife Inc. common stock that have become payable, but receipt of which the director has deferred. Read SEC document |
| January 14, 2022 Filed Jan 19, 2022 21:21 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantDeferred Stock Units · Derivative | 119.265 | $230.58 | $27,500.12 |
DisclosureSEC source: 0001209191-22-003717 · doc4.xml · derivative · entry 1 MCKENZIE DIANA · CIK 0001754648 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 793.664 Underlying: Common Stock · 119.265 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death. F1 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death. F1 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 21:38 UTC | METLIFE INC MET · Entity 488 | GrantCommon Stock | 594 | $63.23 | $37,558.62 |
DisclosureSEC source: 0000937834-22-000012 · wf-form4_164141870397495.xml · nonDerivative · entry 1 MCKENZIE DIANA · CIK 0001754648 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,720 F1 · kind: MetLife, Inc.'s non-management director compensation arrangements pay 50% of non-management director retainer fees in MetLife, Inc. common stock. The director deferred receipt under the MetLife Deferred Compensation Plan for Non-Management Directors. Read SEC document |
| December 14, 2021 Filed Dec 16, 2021 21:33 UTC | METLIFE INC MET · Entity 488 | GrantCommon Stock | 87 | $60.80 | $5,289.60 |
DisclosureSEC source: 0001099219-21-000351 · wf-form4_163969039629364.xml · nonDerivative · entry 1 MCKENZIE DIANA · CIK 0001754648 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,126 F1 · kind: Imputed reinvestment of dividends on deferred shares pursuant to the MetLife Deferred Compensation Plan for Non-Management Directors. Deferred shares represent shares of MetLife, Inc. common stock that have become payable, but receipt of which the director has deferred. Read SEC document |
| October 15, 2021 Filed Oct 18, 2021 20:06 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantDeferred Stock Units · Derivative | 151.041 | $182.07 | $27,500.03 |
DisclosureSEC source: 0001209191-21-060704 · doc4.xml · derivative · entry 1 MCKENZIE DIANA · CIK 0001754648 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 674.399 Underlying: Common Stock · 151.041 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death. F1 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death. F1 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 20:29 UTC | METLIFE INC MET · Entity 488 | GrantCommon Stock | 600 | $62.52 | $37,512.00 |
DisclosureSEC source: 0001099219-21-000322 · wf-form4_163346576952504.xml · nonDerivative · entry 1 MCKENZIE DIANA · CIK 0001754648 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,038 F1 · kind: MetLife, Inc.'s non-management director compensation arrangements pay 50% of non-management director retainer fees in MetLife, Inc. common stock. The director deferred receipt under the MetLife Deferred Compensation Plan for Non-Management Directors. Read SEC document |
| September 14, 2021 Filed Sep 16, 2021 20:39 UTC | METLIFE INC MET · Entity 488 | GrantCommon Stock | 82 | $60.78 | $4,983.96 |
DisclosureSEC source: 0001099219-21-000294 · wf-form4_163182473735592.xml · nonDerivative · entry 1 MCKENZIE DIANA · CIK 0001754648 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,438 F1 · kind: Imputed reinvestment of dividends on deferred shares pursuant to the MetLife Deferred Compensation Plan for Non-Management Directors. Deferred shares represent shares of MetLife, Inc. common stock that have become payable, but receipt of which the director has deferred. Read SEC document |
| July 15, 2021 Filed Jul 16, 2021 20:06 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantDeferred Stock Units · Derivative | 138.889 | $198.00 | $27,500.02 |
DisclosureSEC source: 0001209191-21-046901 · doc4.xml · derivative · entry 1 MCKENZIE DIANA · CIK 0001754648 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 523.358 Underlying: Common Stock · 138.889 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death. F1 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death. F1 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death. Read SEC document |
| June 22, 2021 Filed Jun 24, 2021 18:26 UTC | Change Healthcare Inc. CHNG · Entity 15437 | GrantCommon Stock | 7,136 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-21-005917 · form4.xml · nonDerivative · entry 1 MCKENZIE DIANA · CIK 0001754648 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,048 F1 · shares: Represents the grant of deferred stock units that vests on June 22, 2022. The shares subject to the units will be issued to the Reporting Person after the Reporting Person's separation from service from the Issuer. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 21:19 UTC | METLIFE INC MET · Entity 488 | GrantCommon Stock | 589 | $63.77 | $37,560.53 |
DisclosureSEC source: 0001099219-21-000248 · wf-form4_162396470105710.xml · nonDerivative · entry 1 MCKENZIE DIANA · CIK 0001754648 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,357 F1 · kind: MetLife, Inc.'s non-management director compensation arrangements pay 50% of non-management director retainer fees in MetLife, Inc. common stock. The director deferred receipt under the MetLife Deferred Compensation Plan for Non-Management Directors. Read SEC document |
| June 14, 2021 Filed Jun 17, 2021 00:58 UTC | METLIFE INC MET · Entity 488 | GrantCommon Stock | 73 | $63.31 | $4,621.63 |
DisclosureSEC source: 0001099219-21-000216 · wf-form4_162389147905274.xml · nonDerivative · entry 1 MCKENZIE DIANA · CIK 0001754648 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,768 F1 · kind: Imputed reinvestment of dividends on deferred shares pursuant to the MetLife Deferred Compensation Plan for Non-Management Directors. Deferred shares represent shares of MetLife, Inc. common stock that have become payable, but receipt of which the director has deferred. Read SEC document |
| May 01, 2021 Filed May 4, 2021 20:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 1,842 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-029865 · doc4.xml · nonDerivative · entry 1 MCKENZIE DIANA · CIK 0001754648 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,277 F1 · shares: Restricted stock unit award that vests, subject to certain limited exceptions, on the first anniversary of the grant date. Read SEC document |
| April 15, 2021 Filed Apr 16, 2021 20:03 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantDeferred Stock Units · Derivative | 124.904 | $220.17 | $27,500.11 |
DisclosureSEC source: 0001209191-21-026940 · doc4.xml · derivative · entry 1 MCKENZIE DIANA · CIK 0001754648 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 384.469 Underlying: Common Stock · 124.904 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death. F1 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death. F1 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death. Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 20:58 UTC | METLIFE INC MET · Entity 488 | GrantCommon Stock | 609 | $61.60 | $37,514.40 |
DisclosureSEC source: 0001099219-21-000161 · wf-form4_161765623642029.xml · nonDerivative · entry 1 MCKENZIE DIANA · CIK 0001754648 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,695 F1 · kind: MetLife, Inc.'s non-management director compensation arrangements pay 50% of non-management director retainer fees in MetLife, Inc. common stock. The director deferred receipt under the MetLife Deferred Compensation Plan for Non-Management Directors. Read SEC document |
| March 15, 2021 Filed Mar 17, 2021 20:59 UTC | METLIFE INC MET · Entity 488 | GrantCommon Stock | 69 | $60.54 | $4,177.26 |
DisclosureSEC source: 0001099219-21-000130 · wf-form4_161601474458010.xml · nonDerivative · entry 1 MCKENZIE DIANA · CIK 0001754648 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,086 F1 · kind: Imputed reinvestment of dividends on deferred shares pursuant to the MetLife Deferred Compensation Plan for Non-Management Directors. Deferred shares represent shares of MetLife, Inc. common stock that have become payable, but receipt of which the director has deferred. Read SEC document |
| January 15, 2021 Filed Jan 19, 2021 21:41 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantDeferred Stock Units · Derivative | 121.086 | $225.99 | $27,364.23 |
DisclosureSEC source: 0001209191-21-004031 · doc4.xml · derivative · entry 1 MCKENZIE DIANA · CIK 0001754648 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 259.565 Underlying: Common Stock · 121.086 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death. F1 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death. F1 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death. Read SEC document |
| January 04, 2021 Filed Jan 5, 2021 21:32 UTC | METLIFE INC MET · Entity 488 | GrantCommon Stock | 814 | $46.08 | $37,509.12 |
DisclosureSEC source: 0001099219-21-000031 · wf-form4_160988226364740.xml · nonDerivative · entry 1 MCKENZIE DIANA · CIK 0001754648 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,017 F1 · kind: MetLife, Inc.'s non-management director compensation arrangements pay 50% of non-management director retainer fees in MetLife, Inc. common stock. The director deferred receipt under the MetLife Deferred Compensation Plan for Non-Management Directors. Read SEC document |
| December 14, 2020 Filed Dec 16, 2020 22:07 UTC | METLIFE INC MET · Entity 488 | GrantCommon Stock | 81 | $45.84 | $3,713.04 |
DisclosureSEC source: 0001099219-20-000384 · wf-form4_160815645124539.xml · nonDerivative · entry 1 MCKENZIE DIANA · CIK 0001754648 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,203 F1 · kind: Represents imputed reinvestment of dividends on deferred shares in the reporting person's deferral account pursuant to the MetLife Deferred Compensation Plan for Non-Management Directors. Deferred shares represent shares of MetLife, Inc. common stock that have become payable, but that remain unpaid because payment has been deferred. Read SEC document |
| October 15, 2020 Filed Oct 19, 2020 20:13 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantDeferred Stock Units · Derivative | 112.204 | $222.81 | $25,000.17 |
DisclosureSEC source: 0001209191-20-055261 · doc4.xml · derivative · entry 1 MCKENZIE DIANA · CIK 0001754648 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138.479 Underlying: Common Stock · 112.204 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death. F1 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death. F1 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death. Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 21:40 UTC | METLIFE INC MET · Entity 488 | GrantCommon Stock | 1,007 | $37.26 | $37,520.82 |
DisclosureSEC source: 0001099219-20-000350 · wf-form4_160193400989121.xml · nonDerivative · entry 1 MCKENZIE DIANA · CIK 0001754648 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,121 F1 · kind: The reporting person acquired these deferred shares under MetLife, Inc.'s non-management director compensation arrangements, which provide for 50% of non-management director retainer fees to be paid in MetLife, Inc. common stock, and the MetLife Deferred Compensation Plan for Non-Management Directors, under which directors may elect to defer receipt of such stock for a specified period of time. Read SEC document |
| September 14, 2020 Filed Sep 16, 2020 20:25 UTC | METLIFE INC MET · Entity 488 | GrantCommon Stock | 83 | $38.84 | $3,223.72 |
DisclosureSEC source: 0001099219-20-000312 · wf-form4_160028794144053.xml · nonDerivative · entry 1 MCKENZIE DIANA · CIK 0001754648 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,114 F1 · kind: Represents imputed reinvestment of dividends on deferred shares in the reporting person's deferral account pursuant to the MetLife Deferred Compensation Plan for Non-Management Directors. Deferred shares represent shares of MetLife, Inc. common stock that have become payable, but that remain unpaid because payment has been deferred. Read SEC document |
| July 15, 2020 Filed Jul 17, 2020 20:12 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantDeferred Stock Units · Derivative | 26.275 | $292.77 | $7,692.53 |
DisclosureSEC source: 0001209191-20-042799 · doc4.xml · derivative · entry 1 MCKENZIE DIANA · CIK 0001754648 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26.275 Underlying: Common Stock · 26.275 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death. F1 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death. F1 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death. Read SEC document |
| June 17, 2020 Filed Jun 19, 2020 20:41 UTC | Change Healthcare Inc. CHNG · Entity 15437 | GrantCommon Stock | 14,486 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-20-002930 · form4.xml · nonDerivative · entry 1 MCKENZIE DIANA · CIK 0001754648 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,912 F1 · shares: Represents the grant of deferred stock units that vests on June 17, 2021. The shares subject to the units will be issued to the Reporting Person after the Reporting Person's separation from service from the Issuer. Read SEC document |
| June 16, 2020 Filed Jun 18, 2020 20:52 UTC | METLIFE INC MET · Entity 488 | GrantCommon Stock | 970 | $38.69 | $37,529.30 |
DisclosureSEC source: 0001099219-20-000275 · wf-form4_159251352832502.xml · nonDerivative · entry 1 MCKENZIE DIANA · CIK 0001754648 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,031 F1 · kind: The reporting person acquired these deferred shares under MetLife, Inc.'s non-management director compensation arrangements, which provide for 50% of non-management director retainer fees to be paid in MetLife, Inc. common stock, and the MetLife Deferred Compensation Plan for Non-Management Directors, under which directors may elect to defer receipt of such stock for a specific period of time. Read SEC document |
| June 12, 2020 Filed Jun 16, 2020 21:00 UTC | METLIFE INC MET · Entity 488 | GrantCommon Stock | 74 | $37.45 | $2,771.30 |
DisclosureSEC source: 0001099219-20-000243 · wf-form4_159234119627548.xml · nonDerivative · entry 1 MCKENZIE DIANA · CIK 0001754648 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,061 F1 · kind: Represents imputed reinvestment of dividends on deferred shares in the reporting person's deferral account pursuant to the MetLife Deferred Compensation Plan for Non-Management Directors. Deferred shares represent shares of MetLife, Inc. common stock that have become payable, but that remain unpaid because payment has been deferred. Read SEC document |
| June 03, 2020 Filed Jun 5, 2020 21:39 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 1,435 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-034747 · doc4.xml · nonDerivative · entry 1 MCKENZIE DIANA · CIK 0001754648 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,435 F1 · shares: Restricted stock unit award that vests, subject to certain limited exceptions, on the first anniversary of the grant date. Read SEC document |
| April 01, 2020 Filed Apr 2, 2020 21:23 UTC | METLIFE INC MET · Entity 488 | GrantCommon Stock | 1,345 | $27.90 | $37,525.50 |
DisclosureSEC source: 0001099219-20-000186 · wf-form4_158586257947262.xml · nonDerivative · entry 1 MCKENZIE DIANA · CIK 0001754648 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,987 F1 · kind: The reporting person acquired these deferred shares under MetLife, Inc.'s non-management director compensation arrangements, which provide for 50% of non-management director retainer fees to be paid in MetLife, Inc. common stock, and the MetLife Deferred Compensation Plan for Non-Management Directors, under which directors may elect to defer receipt of such stock for a specific period of time. Read SEC document |
| March 13, 2020 Filed Mar 18, 2020 01:12 UTC | METLIFE INC MET · Entity 488 | GrantCommon Stock | 63 | $31.93 | $2,011.59 |
DisclosureSEC source: 0001099219-20-000156 · wf-form4_158449390692399.xml · nonDerivative · entry 1 MCKENZIE DIANA · CIK 0001754648 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,642 F1 · kind: Represents imputed reinvestment of dividends on deferred shares in the reporting person's deferral account pursuant to the MetLife Deferred Compensation Plan for Non-Management Directors. Deferred shares represent shares of MetLife, Inc. common stock that have become payable, but that remain unpaid because payment has been deferred. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 21:51 UTC | METLIFE INC MET · Entity 488 | GrantCommon Stock | 727 | $51.62 | $37,527.74 |
DisclosureSEC source: 0001099219-20-000046 · wf-form4_157834745741825.xml · nonDerivative · entry 1 MCKENZIE DIANA · CIK 0001754648 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,579 F1 · kind: The Reporting Person acquired these Deferred Shares under MetLife, Inc.'s non-management Director compensation arrangements, which provide for 50% of non-management Director retainer fees to be paid in MetLife, Inc. common stock, and the MetLife Deferred Compensation Plan for Non-Management Directors, under which Directors may elect to defer receipt of such stock for a specific period of time. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.